Home › Acute Coronary Syndrome › NCT06481943

A Prospective Research Investigation of Ischemia Using MCG

A Prospective Research Investigation of Ischemia Using SandboxAQ Magnetocardiography Device

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

* Scheduled to undergo a diagnostic angiography or revascularization procedure for the diagnosis or treatment of ischemia or acute myocardial infarction
* Ability for participant to comply with study requirements
* Patient consented before the planned, clinically indicated cath-lab procedure begins to allow sufficient time for study related activities
* Written informed consent

Exclusion Criteria:

* Present STEMI
* Pregnant or breastfeeding
* Having an active atrial fibrillation episode as seen on most current 12-lead ECG
* Active thoracic metal implant
* Poor access to follow-up

About the study

PRISM is a prospective, pilot research study that aims to systematically characterize the usefulness of CardiAQ MCG, a bedside magnetocardiography device, in the evaluation of myocardial ischemia and infarction status.

What is being tested

• Sponsor MCG device (CardiAQ) (device)

Sponsor: SB Technology, Inc. · Participants: 335 · Started: Jul 11, 2024

Contact the study team

• Maggie LeDang · Phone: 408-981-8754

Official record on ClinicalTrials.gov — NCT06481943

Locations in the U.S.

Conditions

• Acute Coronary Syndrome

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.